Delphinidin Cyclodextrin Complex for Anti-inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory and immunosuppressant treatments, such as hydrocortisone, have adverse effects like increased blood pressure and cardiac arrhythmias when used long-term, necessitating the search for alternative or supplementary solutions that are effective yet safer.
Innovation Solution
Compositions comprising delphinidin and sulfoalkyl ether β-cyclodextrin, which can be administered alone or with other therapeutic agents, offer anti-inflammatory and immunosuppressant properties, reducing inflammation and immune response without the adverse effects of hydrocortisone, and are formulated for controlled release to enhance stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydrocortisone is used for long-term anti-inflammatory and immunosuppressive treatment, then therapeutic efficacy is maintained, but adverse effects such as increased blood pressure and cardiac arrhythmias occur
Solution Approach 1:
The patent extracts the beneficial anti-inflammatory and immunosuppressive properties of hydrocortisone while eliminating its harmful metabolic side effects by using delphinidin, a natural anthocyanidin compound, as an alternative active ingredient that does not cause water retention, hypertension, or cardiac arrhythmias
Solution Approach 2:
The patent employs delphinidin, a naturally occurring compound from plant sources, as a short-term alternative to long-term hydrocortisone use, providing effective inflammation control without the cumulative adverse effects of prolonged corticosteroid therapy
2Duration of action of stationary object
If hydrocortisone is administered internally for prolonged periods, then inflammation is suppressed, but water retention and blood pressure increase occur
Solution Approach 1:
The patent separates the desired anti-inflammatory effect from the harmful water-retention side effect by substituting hydrocortisone with delphinidin, which suppresses inflammation through different mechanisms that do not involve mineralocorticoid activity or sodium-water retention
3Reliability
If delphinidin is administered without complexation, then anti-inflammatory effect is achieved, but solubility and stability are insufficient
Solution Approach 1:
The patent creates a composite material by complexing delphinidin with sulfoalkyl ether β-cyclodextrin, forming an inclusion complex that combines the anti-inflammatory properties of delphinidin with the solubility-enhancing and stability-providing characteristics of the cyclodextrin carrier
Solution Approach 2:
The sulfoalkyl ether β-cyclodextrin acts as an intermediary substance that facilitates the delivery of delphinidin by improving its solubility in aqueous environments and protecting it from degradation, thereby enabling effective administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Delphinidin and sulfoalkyl ether β-cyclodextrin compositions effectively reduce inflammation and immune response, providing a safer alternative to hydrocortisone by minimizing adverse effects like hypertension and cardiac arrhythmias, while maintaining therapeutic efficacy, as demonstrated by in vitro and in vivo experimental results.
Implementation Method 1
a complex composed of delphinidin and a sulfoalkyl ether β-cyclodextrin
Data Source
AI summary
The invention relates to a composition comprising a complex of delphinidin and a sulfoalkyl ether β-cyclodextrin for use as an antiphlogistic and/or immunosuppressive.